U.S. patent application number 16/263757 was filed with the patent office on 2019-07-18 for method of synthesising adcs using affinity resins.
The applicant listed for this patent is ADC Biotechnology Ltd.. Invention is credited to David J. Evans, Colin M. McKee.
Application Number | 20190216819 16/263757 |
Document ID | / |
Family ID | 48626896 |
Filed Date | 2019-07-18 |
![](/patent/app/20190216819/US20190216819A1-20190718-C00001.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00002.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00003.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00004.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00005.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00006.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00007.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00008.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00009.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00010.png)
![](/patent/app/20190216819/US20190216819A1-20190718-C00011.png)
View All Diagrams
United States Patent
Application |
20190216819 |
Kind Code |
A1 |
Evans; David J. ; et
al. |
July 18, 2019 |
METHOD OF SYNTHESISING ADCS USING AFFINITY RESINS
Abstract
This invention relates to a solid phase method of synthesising
biomolecule-drug-conjugates. In particular, this invention relates
to a solid phase method of synthesising antibody-drug-conjugates
(ADCs). This invention also relates to intermediate methods of
producing immobilised, chemically modified biomolecules, e.g.
antibodies. The invention also relates to various uses of capture
resins and to biomolecule-drug-conjugates, intermediate products
and compositions of the methods of the invention.
Inventors: |
Evans; David J.; (Chester,
GB) ; McKee; Colin M.; (Colwyn Heights, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ADC Biotechnology Ltd. |
St. Asaph |
|
GB |
|
|
Family ID: |
48626896 |
Appl. No.: |
16/263757 |
Filed: |
January 31, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14786387 |
Oct 22, 2015 |
10201544 |
|
|
PCT/GB2014/051304 |
Apr 25, 2014 |
|
|
|
16263757 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/6855 20170801;
A61K 47/6803 20170801; C07K 16/2863 20130101; A61K 38/05 20130101;
A61K 31/5365 20130101; A61K 47/6849 20170801; C07K 16/40
20130101 |
International
Class: |
A61K 31/5365 20060101
A61K031/5365; A61K 47/68 20060101 A61K047/68; A61K 38/05 20060101
A61K038/05; C07K 16/40 20060101 C07K016/40; C07K 16/28 20060101
C07K016/28 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 26, 2013 |
GB |
1307574.2 |
Claims
1-31. (canceled)
32. A method of synthesising an antibody-DM1-conjugate, the method
comprising: (i) contacting an antibody with FAbsorbent F1P HF
resin, MAbsorbent A1P resin, MAbsorbent A2P resin or a capture
resin comprising a capture moiety for the antibody, wherein the
capture moiety is: a branched ligand scaffold of formula:
##STR00010## wherein R.sup.1 and R.sup.2 are the same or different
and are each optionally substituted alkyl or aryl ligands, and
R.sup.3 is a solid support optionally attached by a spacer motif;
or a branched triazyl scaffold of formula: ##STR00011## wherein Q
represents the attachment point to a solid support matrix,
optionally with a spacer motif and Groups A and B are phenyl or
naphthyl groups substituted with one or more substituents capable
of hydrogen bonding; under conditions suitable to immobilise the
antibody and therefore provide immobilised antibody; (ii) reacting
the antibody with a crosslinker moiety to provide an activated,
immobilised antibody; (iii) contacting the activated, immobilised
antibody with DM1 to form an immobilised antibody-DM1-conjugate;
and (iv) releasing the antibody-DM1-conjugate from the capture
resin.
33. The method of claim 32, wherein step (i) comprises incubating
antibody with the capture resin.
34. The method of claim 33, wherein the incubation is carried out
at temperature from 10 to 40.degree. C.
35. The method of claim 33, wherein the incubation is carried out
at temperature from 15 to 37.degree. C.
36. The method of claim 33, wherein the incubation is performed for
a period of time of 10 minutes to 18 hours.
37. The method of claim 33, wherein the incubation is carried out
in a buffer solution.
38. The method of claim 37, wherein the buffer solution is
phosphate buffered saline (PBS).
39. The method of claim 33, wherein the incubation is carried out
at a pH range of from 5 to 8.
40. The method of claim 32, wherein after step (i) the immobilised
antibody is washed to remove any antibody that has not been
immobilised on the capture resin.
41. The method of claim 31, wherein the crosslinker moiety is
succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(SMCC).
42. The method of claim 41, wherein step (ii) is carried out in a
buffer solution.
43. The method of claim 42, wherein the buffer solution is
phosphate buffered saline (PBS).
44. The method of claim 41, wherein step (ii) is carried out at a
pH of from 7 to 8.
45. The method of claim 41, wherein step (ii) is carried out in the
presence of a chelating agent.
46. The method of claim 45, wherein the chelating agent is
EDTA.
47. The method of claim 32, wherein after step (ii) the activated,
immobilised antibody is washed to remove any crosslinker
moiety.
48. The method of claim 32, wherein step (iii) comprises contacting
the immobilised antibody with DM1 in a buffer solution.
49. The method of claim 32, wherein step (iii) comprises contacting
the immobilised antibody with DM1 at a pH of from 7 to 8,
preferably 7.4.
50. The method of claim 32, wherein step (iii) is carried out in
the presence of a chelating agent.
51. The method of claim 50, wherein the chelating agent is
EDTA.
52. The method of claim 32, wherein step (iii) comprises incubating
the immobilised antibody with DM1 for a period of time from 6 hours
to 18 hours.
53. The method of claim 32, wherein after step (iii) immobilised
antibody-DM1-conjugate is washed to remove any unreacted DM1.
54. The method of claim 32, wherein step (iv) comprises altering
the pH to break the support-antibody bond.
55. The method of claim 54, wherein the pH is decreased to less
than pH 5.
56. The method of claim 55, wherein the pH is decreased to pH
3.
57. The method of claim 55, wherein the eluted
antibody-DM1-conjugate is neutralised after the step of releasing
the conjugate from the capture resin.
58. The method of claim 57, wherein the antibody-DM1-conjugate is
captured into 2% v/v of 1 M tris(hydroxymethyl)aminoethane
(TRIS).
59. The method of claim 32, wherein the ligand of the capture resin
has a structure: ##STR00012##
60. The method of claim 32, wherein the antibody is a monoclonal
antibody.
61. The method of claim 32, wherein the antibody is trastuzumab.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Ser. No.
14/786,387, filed Oct. 22, 2015, now U.S. Pat. No. 10,201,544,
which is the U.S. national phase of International Patent
Application No. PCT/GB2014/051304, filed Apr. 25, 2014, which
claims priority to United Kingdom Patent Application Serial number
GB 1307574.2, filed Apr. 26, 2013.
[0002] This invention relates to a solid phase method of
synthesising biomolecule-drug-conjugates. In particular, this
invention relates to a solid phase method of synthesising
antibody-drug-conjugates (ADCs). This invention also relates to
intermediate methods of producing immobilised, chemically modified
biomolecules, e.g. antibodies.
[0003] In addition to the above methods, the invention relates to
various uses of capture resins, biomolecule-drug-conjugates,
intermediate products, and compositions of the methods of the
invention.
BACKGROUND
[0004] Immunotoxins and antibody drug conjugates (ADCs) are
proteinaceous drugs combining a target-specific binding domain with
a drug molecule of sufficient potent toxicity that it may be
classed as cytotoxic. Antibodies are the ideal biomolecule for this
purpose creating a targeting system combining high specificity with
high antigen affinity allowing the transportation of the cytotoxic
drug direct to the site of desired administration. These drug
constructs are potentially therapeutic against diseases, finding
particular prevalence within oncology.
[0005] The main criteria of an Antibody Drug Conjugate (ADC) are
that the toxin `warhead` (drug) has activity at extremely low
levels (picoM). Furthermore, it is advantageous to have efficacy
towards tumours cells irrespective of the point in the cycle. For
this purpose DNA active agents have found favour as toxin
candidates as DNA damage, unless repairable, will drive apoptosis
irrespective of the point in the cycle.
[0006] In principle, a suitable toxin for an ADC can be any moiety
defined as a L01 ATC molecule (`Anatomical Therapeutic Chemical
Classification System` where L01 is a subgroup defining
antineoplastic and immunomodulating agents, defined by WHO
Collaborating Centre for Drug Statistics Methodology).
Alternatively, other moieties that may be categorised as suitable
payloads for ADCs may be simply defined as anything that is toxic
to cells once internalised. Most moieties falling in the latter
category would lack sufficient potency to be effective. Hence,
there is an industry trend to identify and exploit `ultra-potency`
materials.
[0007] An expert review on the rationale, design and effectiveness
of immunotoxin and ADC research can be found within: J. Adair et
al, Expert Opin. Biol. Ther., 2012, 12(9): P1191-206, G. Casi et
al, Journal of Controlled Release, 2012, 161, 2, P422-428 and F.
Dosio et al, Toxins, 2011, 3, P848-883.
[0008] A number of solution-phase methods can be used to
manufacture biomolecule-drug-conjugates, e.g.
antibody-drug-conjugates (ADCs). However, solution phase methods
are themselves wasteful in terms of generating large volumes of
waste and are problematic in terms of aggregation of the
biomolecule-drug-conjugates during synthesis.
[0009] The first step in a solution-phase method for manufacturing
biomolecule-drug-conjugates generally involves chemical
modification or activation of the biomolecule. For example, where
the biomolecule is an antibody, the antibody can be `chemically
modified` or `activated` by reducing or partially reducing the
antibody. A suitable process for partial reduction of antibodies is
given in "Bioconjugate Techniques", page 96/97, Greg T. Hermanson,
Academic Press; 2nd edition, 2008, ISBN-13: 978-0123705013. A
reducing agent such as TCEP is generally employed in the reduction
process.
[0010] After chemical modification or activation of the antibody,
e.g. reduction, the next step is to remove any excess
activation/chemical modification agent, e.g. excess reducing agent.
This step is very time consuming as it is sometimes necessary to
run the sample through a separation column multiple times. This can
also be problematic in terms of degradation if stability of the
biomolecule is an issue. The issue of purification of the
chemically modified/activated biomolecule is particularly
problematic if the process involves the full reduction of a ThiomAb
with a large excess of a reducing agent.
[0011] After the above purification step, the chemically
modified/activated, e.g. reduced, antibody is then be conjugated
with a drug moiety. The major problem with this step is the high
probability of aggregation of the biomolecule-drug-conjugate. This
is particularly problematic when highly hydrophobic drugs are
employed in the process. Aggregation is a major problem as it can
lead to unusable biomolecule-drug-conjugates. In the best case
scenario, biomolecule-drug-conjugates contaminated with
biomolecule-drug-conjugate aggregates must be further purified to
remove the aggregates, which is both time consuming and very
wasteful. A large proportion of the drug will be lost during
purification as it forms part of the aggregated
biomolecule-drug-conjugate. In the worst case the entire batch of
biomolecule-drug-conjugate contaminated with
biomolecule-drug-conjugate aggregate to such a high degree it is
entirely unusable and must be disposed of.
[0012] Oncologists have been working on harnessing target-specific
monoclonal antibodies to deliver cytotoxic drugs to the site of
tumors as long as monoclonal antibodies have existed; nearly three
decades. Up until now three classes of toxin have dominated the
field. Namely, calicheamicins, maytansines and auristatins. These
cytotoxic drug classes are all typically hydrophobic in nature.
When conjugated to an antibody their presence increases the overall
hydrophobicity of the antibody significantly and in some cases to
the extent that hydrophobic interactions between conjugates leads
to conjugate aggregation. The order of significance of this issue
is Calicheamicin>Maytansine>Auristatin based on the knowledge
that the processes for both Mylotarg and CMC-544 contain
chromatographic aggregate removal steps. Approximately 50% of
maytansine processes contain aggregate removal steps and very few
auristatin processes contain aggregate removal steps.
[0013] More recently, toxins based on duocarmycins
(www.syntarga.com) and pyrollebenzodiazepene (PBD) dimers
(www.spirogen.com) have been conjugated to antibodies and are
undergoing pre-clinical evaluation. These new classes of toxin are
even more hydrophobic than their predecessor cytotoxin drug classes
and are more prone to aggregation when conjugated to
antibodies.
[0014] Significant efforts have been focussed on modulation of the
hydrophobicity of the drug by incorporating hydrophilic linkers
(Zhao et al, J. Med. Chem., 2011, 54, 10, 3606-3623). Where
aggregate formation cannot be controlled developers have relied on
well-known techniques for aggregate removal from protein based
therapeutics. These include a range of different chromatographic
separations including ion exchange, hydrophobic interaction,
hydroxyapatite and others well known to those in the art.
Undertaking such chromatographic purification techniques has the
result of achieving adequate product quality but at the expense of
process yield. When working with antibodies and antibody based
therapeutics in the context of manufacturing physical loss of
material through ambiguous, incidental side reactions or unwanted
physiochemical interactions has a hugely significant financial
impact.
[0015] Accordingly, the conventional solution-phase processes for
manufacturing biomolecule-drug-conjugate are beset with
difficulties and it would be desirable to provide an improved
process for manufacturing biomolecule-drug-conjugates.
[0016] The present invention addresses one or more of the above
issues with the conventional solution-phase methods.
BRIEF SUMMARY OF THE DISCLOSURE
[0017] Method of Synthesising a Biomolecule-Drug-Conjugate:
[0018] In accordance with the present invention there is provided a
method of synthesising a biomolecule-drug-conjugate, the method
comprising:
(i) contacting a biomolecule with a capture resin under conditions
suitable to immobilise the biomolecule and therefore provide an
immobilised biomolecule; wherein the biomolecule is an antibody,
modified antibody or antibody fragment; and wherein the capture
resin comprises a biomolecule capture moiety selected from the
group consisting of: (1) a non-peptide-based, including amino
acid-based, Protein A, Protein G or Protein L mimetic, (2) a
peptide-based Protein A, Protein G or Protein L mimetic, (3) a
nucleotide binding site capture moiety and (4) a glycoprotein
capture moiety; (ii) optionally contacting the immobilised
biomolecule with a chemical modification agent or activating agent
to provide a chemically modified or activated, immobilised
biomolecule; (iii) contacting the immobilised biomolecule or the
chemically modified or activated, immobilised biomolecule with a
drug component to form an immobilised biomolecule-drug-conjugate;
(iv) releasing the biomolecule-drug-conjugate from the capture
resin.
[0019] A key feature of the above method of the invention is that
the capture resin employed in the process is able to immobilise the
biomolecule in a consistent and reproducible manner. Consistent
immobilisation of the biomolecule to the capture resin should
result in reduced variation in the resulting
biomolecule-drug-conjugate produced by the above method. For
example, the variation in the point at which the drug component is
attached to the immobilised biomolecule might be reduced, thus
leading to a more consistent point of attachment between the drug
component and the immobilised biomolecule. Such an improvement in
regio-specificity would be desirable in terms of improving the
consistency of the resulting biomolecule-drug-conjugate
product.
[0020] The employment of a non-peptide-based Protein A, Protein G
or Protein L mimetic or a peptide-based Protein A, Protein G or
Protein L mimetic (i.e. (1) or (2) in the first step of the above
method) as the biomolecule capture moiety, as opposed to the
employment of the parent Protein A, Protein G or Protein L as the
biomolecule capture moiety, may lead to a relative improvement in
consistency in the immobilisation of the biomolecule due to
increased regio-specificity of the mimetic verses the conventional
Protein A, Protein G or Protein L based systems. In cases in which
the regio-specificity of the immobilisation of biomolecules to
proteins is low, the employment of the parent Protein A, Protein G
or Protein L as the biomolecule capture moiety would inherently
result in variable immobilisation of the biomolecule to the capture
resin. For example, the parent Protein A, Protein G or Protein L
may exhibit non-specific binding via other sites on the protein
which may complicate the overall interaction. As explained above,
consistent immobilisation of the biomolecule to the capture resin
as is envisaged in the present invention may then result in reduced
variation in the resulting biomolecule-drug-conjugate produced by
the above method. This would be advantageous. Another advantage of
the resin systems of the present invention resides in the fact that
a wider range of drugs can in principle be conjugated to the resin
than is the case for conventional Protein A, Protein G or Protein L
based systems. For example, in the case of hydrophobic molecules
other non-specific binding that may occur in parent Protein A,
Protein G or Protein L based systems may disrupt or prevent
effective conjugation of such drugs.
[0021] Similar benefits exist for the employment of a nucleotide
binding site capture moiety or a glycoprotein capture moiety (i.e.
(3) or (4) in the first step of the above method) as the
biomolecule capture moiety.
[0022] In an embodiment, the capture resin is a non-proteinaceous
capture resin. In an embodiment, the biomolecule capture moiety of
the capture resin has a molecular weight of about 1000 Da or less,
optionally about 500 Da or less, about 300 Da or less or about 200
Da or less. In an embodiment, the capture resin is a
non-proteinaceous capture resin and the biomolecule capture moiety
of the capture resin has a molecular weight of about 1000 Da or
less.
[0023] Another benefit of employing a non-peptide-based Protein A,
Protein G or Protein L mimetic or a peptide-based Protein A,
Protein G or Protein L as the biomolecule capture moiety, as
opposed to the employment of the parent Protein A, Protein G or
Protein L as the biomolecule capture moiety is that the mimetic
biomolecule capture moieties are compatible with a broad range of
common antibody conjugation chemistries and can be scaled up to
industrial levels. This is in contrast with Protein A, Protein G or
Protein L based biomolecule capture moieties.
[0024] For example, it is often desirable to target the lysyl side
chain functional group on the immobilised antibody. Of the 28
antibody drug conjugates currently in clinical development almost
half (those marked with a * in the table below) employ lysine
directed conjugation chemistry. The proteinaceous nature of an
immobilizing ligand on the surface of Protein A, G or L will result
in the unintentional targeting of the lysyl side chain functional
groups on the protein capture resin. Protein A (swiss-prot P02976)
has 59 Lysine residues, Protein G (swiss-prot P919909) has 59
lysine residues and Protein L (swiss-prot Q51918) has 132 lysine
residues.
TABLE-US-00001 Name Target Drug + Linker Developer Phase Indication
ADCetris CD30 vcE Seattle Genetics MA 2011 HL and ALCL CR011-vcE
GPNMB vcE Celldex Ph II Breast, Melanoma PSMA ADC PSMA vcE
Progenies Ph II Prostate RG7593 CD22 vcE GNE/Roche Ph II
Hematological RG7596 CD79b vcE GNE/Roche Ph II Hematological SGN-75
CD70 mcMMAF Seattle genetics Ph 1b NHL, RCC AGS-5ME SLC44A4 vcE
Agensys Ph I Prostate, Pancreatic AGS-22ME Nectin 4 vcE Agensys Ph
I Solid Tumors AGS-16M8F ENPP3 mcMMAF Agnsys Ph I Renal Cell
Carcinoma BAY 79-4620 MN/CA-9 vcE Bayer Ph I Solid Tumors MLN064
GCC vcE Takeda/Millenium Ph I Gastrointestinal RG7450 STEAP 1 vcE
GNE/Roche Ph I Prostate RG7458 MUC16 vcE GNE/Roche Ph I Ovarian
RG7598 ? Auristatin GNE/Roche Ph I Multiple Myeloma RG7599 ?
Auristatin GNE/Roche Ph I NSCLC, Ovarian RG7600 ? Auristatin
GNE/Roche Ph I Pancreatic, Ovarian RG7636 ? Auristatin GNE/Roche Ph
I Melanoma Kadcyla* Her2 SMCC DM1 GNE/Roche MA 2013 Breast Cancer
Lorvotuzumab* CD56 SPP-DM1 Immunogen Ph II MM, Merkel Cell SAR3419*
CD19 SPDB-DM4 Sanofi Aventis Ph II NHL, B-ALL SAR566658* CA6
SPDB-DM4 Sanofi Aventis Ph I Breast, Ovarian BT-062* CD138 SPDB-DM4
Biotest Ph I Multiple Myeloma IMGN-529* CD37 SPDB-DM4 Immunogen Ph
I NHL IMG-853* FolR1 SPDB-DM4 Immunogen Ph I Ovarian NSCLC
BAY-94-9343* Mesothelin SPDB-DM4 Bayer Ph I Meso tumors AMG-595*
EGFRvIII DM1 Amgen Ph I Recurrent Glioma AMG-172* ? DM1 Amgen Ph I
Renal Cancer CMC-544* CD22 Calicheamicin Pfizer Ph III B-cell
ALL
[0025] In addition to the competition between ligand and antibody
lysyl residues as described above, there are also other issues with
Protein A, G and L based capture resins. These include leaching of
the protein and immunogenicity of leached adducts. This means that
these affinity supports cannot be employed (for purification or
conjugation) towards the end of a manufacturing process. Any
conjugate material furnished from such a process employing Protein
A, G and L based capture resins will not meet current regulatory
guidelines for antibody purification and product quality.
[0026] Method of Synthesising a Chemically Modified an Activated,
Immobilised Biomolecule:
[0027] In accordance with the present invention there is provided a
method of synthesising a chemically modified or an activated,
immobilised biomolecule, the method comprising:
(i) contacting a biomolecule with a capture resin under conditions
suitable to immobilise the biomolecule and therefore provide an
immobilised biomolecule; wherein the biomolecule is an antibody,
modified antibody or antibody fragment; and wherein the capture
resin comprises a biomolecule capture moiety selected from the
group consisting of: (1) a non-peptide-based, including amino
acid-based, Protein A, Protein G or Protein L mimetic, (2) a
peptide-based Protein A, Protein G or Protein L mimetic, (3) a
nucleotide binding site capture moiety and (4) a glycoprotein
capture moiety; and (ii) contacting the immobilised biomolecule
with a chemical modification agent or activating agent to provide a
chemically modified or activated, immobilised biomolecule.
[0028] Conjugation of proteins and more specifically antibodies is
often used in research, diagnostics and therapeutics. Bioconjugate
Techniques, Second Edition (Greg T Hermanson) provides highly
detailed information on the chemistry, reagent systems and
practical applications for creating labelled or conjugate
molecules. It also describes dozens of reactions with details on
hundreds of commercially available reagents and the use of these
reagents for modifying or crosslinking peptides and proteins,
sugars and polysaccharides, nucleic acids and oligonucleotides,
lipids, and synthetic polymers. A brief summary of key conjugation
chemistries applied to antibodies is provided below.
[0029] Conjugation to free thiols after reduction of the native
interchain disulphides is a common approach to antibody conjugation
and the chemistry employed for the commercial ADC ADCetris.RTM.. A
process comprises contacting the antibody with a reductant such as
TCEP, DTT, merceptoethylamine or other suitable reductant well
known in the field followed by conjugation with a drug, ligand,
label of the formula D-X, where D is the drug, ligand or label and
X is a reactive group selected from maleimides, haloalkanes,
pyridyl disulphides and other thiol reactive chemistries known in
the art.
[0030] An alternative approach to thiol conjugation with antibodies
is to engineer reactive cysteine residues at specific sites in
antibodies to allow drugs to be conjugated with defined
stoichiometry without disruption of interchain disulphide bonds.
The engineered cysteines are often present as mixed disulphides of
cysteine or glutathione. The adducts are removed by complete
reduction followed by diafiltration. This breaks the interchain
disulphides which must be reformed by oxidation with air,
CuSO.sub.4 or dehydroascorbic acid.
[0031] Another common site for conjugation are amino groups present
on the side-chain of lysine residues. The simplest approach
comprises contacting the antibody with a drug, ligand, label or
linker of the formula D-Y. D has the same definition as above and Y
is a reactive group selected from isocyanates, NHS esters, sulfonyl
chlorides, epoxides and other reagents known to those skilled in
the art.
[0032] Indirect conjugation to lysines is often also employed. The
amino group of the lysine side chain is first activated with a
heterobifunctional linker before this is conjugated with a drug
containing a complimentary reactive chemistry. Examples of such
couplets include modification of the lysine with 2-iminothiolane to
create a new thiol followed by conjugation with any of the thiol
reactive drug-linkers (D-X) described above. Another couplet is the
modification of lysine with SMCC to create a lysine bound maleimide
followed by conjugation with a drug containing a free thiol. For a
complete review of potential couplets useful for indirect lysine
conjugation see Hermanson and the Perbio cross-linking agent
catalogue.
[0033] Several groups have developed ways to incorporate
non-natural amino acids with side chains that are chemically
orthogonal to the 20 proteogenic amino acid side chains in
proteins.
[0034] Redwood Bioscience (www.redwoodbioscience.com) has developed
a technology they call Aldehyde Tagging. In this they exploit a
natural enzyme called formyl glycine enzyme (FGE) which normally
converts a Cys residue within a highly conserved 13 amino acid
sequence into a formyl glycine (aldehyde) in Type I sulfatases (Wu
et al, PNAS, 2009, 106, 9, 3001). Drugs, ligands or labels to be
conjugated to such modified antibodies must contain aldehyde
reactive chemistries such as oxyamines or hydrazines. A full
disclosure of aldehyde reactive functionalities can be found in
Hermanson and Perbio catalogues.
[0035] Ambryx has developed a technology they call EuCode (Liu et
al, Anu. Rev. Biochem., 2010, 79, 413). EuCode is a platform
whereby cells are engineered to incorporate non-natural amino acids
in heterologous proteins by inclusion of three non-natural
components in the expression system:
1. A non-natural amino acid supplemented into the medium 2. An
orthogonal aminoacyl-tRNA synthetases (aaRS) 3. An orthogonal
tRNA
[0036] The orthogonal aaRS/tRNA pair has been engineered/selected
to promote read through at the amber stop codon and to incorporate
the non-natural amino acid at that position. As many as 70 nnAAs
have been incorporated into protein using this approach. FIG. 5
expands on the possible combination of orthogonal amino acid side
chain and reactive chemistry (adapted from Ambryx presentation at
Hanson Wade ADC summit meeting in February 2012).
[0037] Sutro has described the production of antibodies and
cytokines using an open, cell-free synthesis (OCFS) technology. A
feature of OCFS is the ability to incorporate non-natural amino
acids into the protein with charged tRNAs that can be directed to a
specific codon to deliver the non-natural amino acid to a specific
location on the protein--making the protein amenable to specific
modification or imparting a new desired property (Goerke et al,
Biotechnol. Bioeng., 2008, 99: 351-367).
[0038] Immobilized antibody conjugation is compatible with all
non-natural amino acid side chains and complimentary reactive
chemistries with one proviso. The antibody capture ligand must not
contain the novel chemistry incorporated as part of the non-natural
amino acid side chain.
[0039] Oxidation of polysaccharide residues in glycoproteins with
sodium periodate provides a mild and efficient way of generating
reactive aldehyde groups for subsequent conjugation with amine or
hydrazide containing molecules; drugs, ligands or labels. The
process involve first contacting the antibody with sodium periodate
and then conjugating with reactive groups selected from amines,
hydrazides, aminoxy or other aldehyde reactive chemistries known in
the art.
[0040] Step (i):
[0041] In an embodiment, the step of contacting the biomolecule
with the capture resin comprises incubating the biomolecule with
the capture resin.
[0042] The incubation may be carried out at temperature of from
about 0 to about 100.degree. C., preferably at temperature of from
about 5 to about 50.degree. C. and optionally at temperature of
from about 10 to about 40.degree. C. Ideally, the incubation is
carried out at temperature of from about 15 to about 37.degree. C.,
e.g. the incubation is carried out at room temperature, such as
about 21.degree. C. Alternatively, the incubation is carried out at
about 37.degree. C.
[0043] The incubation may be carried out for a period of time of
from about 1 minute to about 3 days, e.g. for a period of time of
from about 10 minutes to about 18 hours. Preferably the incubation
is carried out for a period of time of from about 20 minutes to
about 1 hour.
[0044] In an embodiment, the incubation is carried out in an
aqueous media. In an alternate embodiment, the incubation is
carried out in a buffer solution such as phosphate buffered saline
(PBS) or any buffering salt compatible with the desired binding pH
and chemistry, optionally the incubation is carried out in a buffer
solution such as phosphate buffered saline (PBS). In an embodiment,
the incubation is carried out using a co-solvent including a
solvent such as DMSO or DMF. The co-solvent may be present within a
range of 0.5-80% v/v, such as 0.5-50% v/v.
[0045] In an embodiment, the incubation is carried out at a pH of
from about 5 to about 10, preferably about 5 to about 8, more
preferably about 6 to about 8 In a preferred embodiment, the
incubation is carried out at a pH of about 6 to about 7.5, ideally
at pH of about 6.5. In another preferred embodiment, the incubation
is carried out at a pH of about 7 to about 8, ideally at pH of
about 7.4. This results in improved binding of the antibody to the
derivatised support.
[0046] In an embodiment, the immobilised biomolecule (i.e. the
biomolecule that is immobilised on the capture resin) is washed to
remove any biomolecule that has not been immobilised on the capture
resin. The washing of the immobilised biomolecule can be affected
by rinsing with fresh solvent. For example, the washing of the
immobilised biomolecule can be affected by rinsing with a buffer
solution such as PBS. Optionally, the rinsing of the immobilised
biomolecule is carried out in the presence of a chelating agent,
such as EDTA. Alternatively, the washing of the immobilised
biomolecule can be affected by rinsing with a `Modification Buffer`
including a sodium phosphate buffer, NaCl and a chelating agent,
such as EDTA.
[0047] Step (ii):
[0048] In an embodiment, the step of contacting the immobilised
biomolecule with a chemical modification agent or an activating
agent to provide a modified or activated, immobilised biomolecule
involves reducing the biomolecule. In an embodiment, the reduction
of the biomolecule involves complete reduction. In an embodiment,
the reduction of the biomolecule involves partial reduction. In an
embodiment, the reduction of the biomolecule involves complete
reduction followed by re-oxidation.
[0049] In an embodiment, the biomolecule is reduced by contacting
it with a reducing agent such as tris(2-carboxyethyl)phosphine
(TCEP), dithiothreitol (DTT), merceptoethylamine or other suitable
reductant. Preferably the reducing agent is
tris(2-carboxyethyl)phosphine (TCEP).
[0050] In an embodiment, the reduced biomolecule is re-oxidised by
contacting it with an oxidising agent such as air, CuSO.sub.4 or
dehydroascorbic acid (DHAA). Preferably the oxidising agent is
dehydroascorbic acid (DHAA).
[0051] In an embodiment, the process of reducing the biomolecule is
carried out in a buffer solution such as phosphate buffered saline
(PBS).
[0052] In an embodiment, the process of reducing the biomolecule is
carried out at a pH of from about 5 to about 10, preferably from
about 7 to about 8, preferably about 7.4.
[0053] In an embodiment, the process of reducing the biomolecule is
carried out in the presence of a chelating agent, such as EDTA.
[0054] In an embodiment, the process of reducing the biomolecule
involves incubating the biomolecule with the reducing agent for a
period of time of from about 20 minutes to about 3 days,
optionally, from about 1 hour to about 2 days and further
optionally from about 6 hours to about 18 hours.
[0055] In an embodiment, the step of contacting the immobilised
biomolecule with a chemical modification agent or an activating
agent to provide a modified or activated, immobilised biomolecule
involves reacting the biomolecule with a crosslinker moiety. For
example, the crosslinker moiety could be an amine-to-sulfhydryl
crosslinker, e.g. a crosslinker having an NHS-ester and a maleimide
reactive group at opposite ends. This method of modifying or
activating the biomolecule effectively results in a
biomolecule-linker-drug-conjugate. Suitable cross-linkers are
generally able to react with a primary amine group on the drug (via
the reactive NHS ester end) and also react with a cysteine residue
on the biomolecule (via the reactive maleimide end). In this
particular example, the maleimide end will react with a cysteine in
the immobilised biomolecule. An example of such a crosslinker is
succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(SMCC).
[0056] In an embodiment, the process of reacting with a crosslinker
is carried out in a buffer solution such as phosphate buffered
saline (PBS). Alternatively, the process of reacting with a
crosslinker is carried out in a `Modification Buffer` including a
sodium phosphate buffer, NaCl and a chelating agent, such as
EDTA.
[0057] In an embodiment, the process of reacting with a crosslinker
is carried out at a pH of from about 7 to about 9, preferably from
about 7 to about 8, preferably about 8.0.
[0058] In an embodiment, the process of reacting with a crosslinker
is carried out in the presence of a chelating agent, such as
EDTA.
[0059] In an embodiment, the process of reacting with a crosslinker
involves incubating the biomolecule with the crosslinker for a
period of time of from about 20 minutes to about 3 days,
optionally, from about 1 hour to about 2 days and further
optionally from about 6 hours to about 18 hours.
[0060] In an embodiment, the step of contacting the immobilised
biomolecule with a chemical modification agent or an activating
agent to provide a modified or activated, immobilised biomolecule
involves reacting the biomolecule with Traut's reagent.
[0061] In an embodiment, the process of reacting with Traut's
reagent is carried out in a buffer solution such as phosphate
buffered saline (PBS).
[0062] In an embodiment, the process of reacting with Traut's
reagent is carried out at a pH of from about 7 to about 9,
preferably from about 7 to about 8, preferably about 8.0.
[0063] In an embodiment, the process of reacting with Traut's
reagent is carried out in the presence of a chelating agent, such
as EDTA.
[0064] In an embodiment, the process of reacting with Traut's
reagent involves incubating the biomolecule with the reducing agent
for a period of time of from about 20 minutes to about 3 days,
optionally, from about 1 hour to about 2 days and further
optionally from about 6 hours to about 18 hours.
[0065] In an embodiment, the activated, immobilised biomolecule is
washed to remove any modification/activating agent. In an
embodiment the washing involves rinsing with a buffer, optionally
wherein the buffer is phosphate buffered saline (PBS). Other
suitable buffers include: Potassium phosphate buffer; Sodium
phosphate buffer; Sodium citrate buffer; Bis-Tris propane buffer;
HEPES buffer; Sodium acetate buffer; Sodium citrate buffer;
Cacodylic acid buffer; Ammonium acetate buffer; Imidazole buffer;
Bicine buffer; and 2-(N-morpholino)ethanesulfonic acid (MES)
buffer. For example, the immobilised biomolecule can be washed with
a buffer solution such as phosphate buffered saline (PBS) at a pH
of from about 7 to about 8, preferably about 7.4. Optionally, the
rinsing of the activated, immobilised biomolecule is carried out in
the presence of a chelating agent, such as EDTA. Another example of
rinsing the activated, immobilised biomolecule involves rinsing the
resin with a buffer such as PBS followed by a `Conjugation Buffer`
which includes sodium citrate, NaCl and a chelating agent such as
EDTA.
[0066] Step (iii):
[0067] In an embodiment, the step of contacting the chemically
modified or activated, immobilised biomolecule with a drug
component to form an immobilised biomolecule-drug-conjugate
involves contacting the chemically modified or activated,
immobilised biomolecule with a drug component in a buffer solution
as hereinbefore described with relation to step (ii).
[0068] In an embodiment, the step of contacting the chemically
modified or activated, immobilised biomolecule with a drug
component to form an immobilised biomolecule-drug-conjugate
involves contacting the chemically modified or activated,
immobilised biomolecule with a drug component at a pH of from about
5 to about 8, preferably about 7 to about 8 and more preferably
about 7.4.
[0069] In an embodiment, the step of contacting the chemically
modified or activated, immobilised biomolecule with a drug
component to form an immobilised biomolecule-drug-conjugate is
carried out in the presence of a chelating agent, such as EDTA.
[0070] In an embodiment, step of contacting the chemically modified
or activated, immobilised biomolecule with a drug component to form
an immobilised biomolecule-drug-conjugate involves incubating the
chemically modified or activated, immobilised biomolecule with drug
component for a period of time of from about 20 minutes to about 3
days, optionally, from about 1 hour to about 2 days and further
optionally from about 6 hours to about 18 hours.
[0071] In an embodiment, the immobilised biomolecule-drug-conjugate
is washed prior to the step of releasing the
biomolecule-drug-conjugate from the capture resin. The washing
removes any unreacted drug component. In an embodiment the washing
involves rinsing with a buffer, optionally wherein the buffer is
phosphate buffered saline (PBS), and other solvent. Other suitable
buffers include: Potassium phosphate buffer; Sodium phosphate
buffer; Sodium citrate buffer; Bis-Tris propane buffer; HEPES
buffer; Sodium acetate buffer; Sodium citrate buffer; Cacodylic
acid buffer; Ammonium acetate buffer; Imidazole buffer; Bicine
buffer; and 2-(N-morpholino)ethanesulfonic acid (MES) buffer. For
example, the immobilised biomolecule-drug-conjugate can be washed
with a buffer solution such as phosphate buffered saline (PBS) and
dimethylacetamide (DMA) at a pH of from about 5 to about 7.
Optionally, the rinsing of the immobilised
biomolecule-drug-conjugate is carried out in the presence of a
chelating agent, such as EDTA.
[0072] Step (iv):
[0073] In an embodiment, the step of releasing the
biomolecule-drug-conjugate from the capture resin involves:
a) exposing the support-biomolecule compound to a release agent;
and/or b) altering the pH to break the support-biomolecule
bond.
[0074] In an embodiment, the release agent is a hydrogen bond
disrupter such as co-solvents of Hexafluoroisopropanol,
2,2,2-Trifluoroethanol or dimethylsulfoxide (DMSO).
[0075] In an embodiment, the release agent is incubated with the
support-biomolecule.
[0076] The incubation may be carried out at temperature of from
about 0 to about 100.degree. C., preferably at temperature of from
about 5 to about 50.degree. C. and optionally at temperature of
from about 10 to about 40.degree. C. Ideally, the incubation is
carried out at temperature of from about 15 to about 37.degree. C.,
e.g. the incubation is carried out at room temperature, such as
about 21.degree. C. Alternatively, the incubation is carried out at
about 37.degree. C.
[0077] The incubation may be carried out for a period of time of
from about 1 minute to about 3 days. Preferably the incubation is
carried out for a period of time of from about 30 minutes to about
2 hours.
[0078] The incubation may be carried out in an aqueous media.
Alternatively, the incubation may be carried out in a solvent such
as DMF, DMSO, MeOH or MeCN. Alternatively, the incubation may be
carried out in an aqueous-solvent mixture with up to 80% solvent,
preferably 0.5 to 50% and most preferred 0.5% to 10% v/v. In
certain cases mixtures of one or more of the above solvents,
including water, may be appropriate. Where necessary a stabiliser
may also be included to ensure the conjugate remains intact.
[0079] In an embodiment, the step of releasing the
biomolecule-drug-conjugate from the capture resin involves altering
the pH. The pH can be altered by any amount that is sufficient to
break the support-biomolecule bond but which will not affect the
activity, integrity or 3D structure of the biomolecule.
[0080] For example, the pH can be adjusted so that it is acidic. In
an embodiment, the pH is decreased from about pH2 to about pH6.
Optionally, the pH is adjusted to be less than about pH 5, e.g.
about pH 3 to about 5, for example less than about pH 4. In an
embodiment, the pH is decreased to about pH 3.
[0081] Alternatively, the pH can be adjusted so that it is basic.
In an embodiment, the pH is increased to about pH8 to about pH10.
Optionally, the pH is adjusted to greater than pH 8. For example,
the pH can be increased to about pH 9. The pH can be increased to
being greater than pH 9. For example, the pH can be increased to
about pH10. The pH can be increased to being greater than pH10, but
usually will be less than pH14.
[0082] The biomolecule-drug-conjugate may undergo one or more
treatments with release agent. Advantageously, the use of a second
or subsequent treatment with fresh release agent may result in
increasing the amount of biomolecule-drug-conjugate released from
the capture resin. Fresh release agent is release agent that has
not previously been incubated with the immobilised
biomolecule-drug-conjugate.
[0083] In an embodiment, the step of releasing the
biomolecule-drug-conjugate from the capture resin involves
contacting the biomolecule-drug-conjugate with a salt. For example,
the biomolecule-drug-conjugate might be contacted with NaCl. The
concentration of the salt can range from about 0.1 to about 10M,
preferably about 0.1 to about 1M.
[0084] In an embodiment, the eluted biomolecule-drug-conjugates is
neutralised after the step of releasing the conjugate from the
capture resin. For example, the conjugate can be captured into 2%
v/v of 1M Tris(hydroxymethyl)aminoethane (TRIS).
[0085] Washing Steps:
[0086] In an embodiment the step of washing an intermediate in the
method of the invention comprises removing substances that are not
bound to the capture resin such as contaminants. Typical
contaminants include excess reagent used to activate the
immobilised biomolecule, biomolecule that has not been immobilised
on the capture resin and drug component that has not reacted with
the activated, immobilised biomolecule. Any medium that does not
affect the activity, integrity or 3D structure of the biomolecule
or the integrity of the binding between the immobilised biomolecule
and the capture resin can be used to wash the intermediate.
[0087] Preferably the buffer is isotonic and induces a stable
environment to biomolecules such as antibodies by mimicking
physiological pH and ionic strength. In an embodiment, the
activated, immobilised biomolecule is washed by filtration.
Optionally, the resultant filtrate is buffer-exchanged, e.g. by
centrifugation using membrane cartridges.
[0088] Typically, additives are introduced to the buffer media.
These additives induce a level of control to the buffer system and
the biomolecule contained within it. For example, additives such as
Tris or histidine are introduced to a buffered process stream to
maintain pH and minimise incidental acidification. Typically, the
pH of a biomolecule process stream should be maintained between pH5
and 9.5, with the extremes of the pH limits avoided for prolonged
periods. Inorganic salts such as 0.1M NaCl(aq) may be added to
maintain the ionic strength of the process stream. Ionic and
non-ionic detergents such as Tween (polysorbate) may be added to
the buffer to favourably increase the solubility of poorly soluble
biomolecules in the buffer media and minimise aggregation.
[0089] A Mixture Comprising a Capture Resin and an Activating
Agent:
[0090] In accordance with the present invention there is provided a
mixture comprising:
(i) a capture resin comprising an antibody, modified antibody or
antibody fragment capture moiety selected from the group consisting
of: (1) a non-peptide-based Protein A, Protein G or Protein L
mimetic, (2) a peptide-based Protein A, Protein G or Protein L
mimetic, (3) a nucleotide binding site capture moiety and (4) a
glycoprotein capture moiety; and (ii) a chemical modification agent
or activating agent.
[0091] In an embodiment, the capture resin includes an immobilised
antibody, modified antibody or antibody fragment on the surface
thereof.
[0092] A Use of a Capture Resin in the Synthesis of a
Biomolecule-Drug-Conjugate:
[0093] In accordance with the present invention there is provided a
use of a capture resin comprising an antibody, modified antibody or
antibody fragment capture moiety selected from the group consisting
of: (1) a non-peptide-based Protein A, Protein G or Protein L
mimetic, (2) a peptide-based Protein A, Protein G or Protein L
mimetic, (3) a nucleotide binding site capture moiety and (4) a
glycoprotein capture moiety in the synthesis of a
biomolecule-drug-conjugate.
[0094] Capture Resin:
[0095] For years researchers have tried to develop ligands that
have affinity for a range of full length antibodies, fragments or
fusions as replacements for traditional Protein A, G or L affinity
purification supports. The main criterion for successful ligand
discovery/development has been:
1. High selectivity for antibodies to afford high initial
purification 2. Useful dynamic binding capacity 3. Elution
conditions compatible with retention of antibody integrity 4.
Stability of support during multiple elution/cleaning cycles 5.
Lowered cost relative to Protein A, G or L supports
[0096] In the context of using these ligands for solid phase
antibody conjugation criterion 1 above is not critical as the
conjugation process starts with purified antibody. However, the
ligand must meet the remaining 4 criterion in full. In addition,
the ligand must ideally have a defined site of interaction with the
antibody which affords suitable affinity binding strength for
conjugation. This attribute is necessary so that the antibody may
be bound to the support and not inadvertently eluted during buffer
replenishment over time. In addition, a defined site of interaction
is desirable to infer consistent conformational presentation of the
bound antibody complex to the surrounding solution phase with the
effect of providing a means for consistent and reproducible
conjugation chemistry. Antibodies are well characterized
biomolecules with a number of well-defined binding domains which
are exploited for affinity purification.
[0097] The first defined region(s) are the Protein A and Protein G
binding pockets which are exploited in affinity chromatography
using Protein A/G and mimetics of Protein A/G supports. Protein A
interacts with the CH2 CH3 interchain domain in the Fc region via
number of non-covalent interactions with amino acid residues: Thr
250, Leu 251, Met 252, Ile 253, His 310, Gin 311, Leu 314, Asn 315,
Lys 338, Glu 345, Ala 431, Leu 432, His 433, Asn 434 and His 435.
Protein A mimetic supports have been rationally designed to
interact with this domain via one or more of the amino acids
defined above. These mimetic supports afford suitable affinity
ligands for IgG binding and conjugation. Protein A mimetic supports
may be defined in sub-classes as incorporating non-peptide, peptide
or amino acid based ligands. Similarly, Protein G interacts with
the CH2 CH3 interchain domain in the Fc region via number of
non-covalent interactions with amino acid residues Ile 253, Ser
254, Gin 311, Glu 380, Glu 382, His 433, Asn 434 and His 435.
Protein G mimetic supports have been rationally designed to
interact with this domain via one or more of the amino acids
described above. Once again these mimetic supports afford suitable
affinity ligands for IgG binding and conjugation. Protein G mimetic
supports may be defined in sub-classes as incorporating
non-peptide, peptide or amino acid based ligands. In an embodiment,
the capture resin is able to bind to a Protein A or a Protein G
binding pocket on a biomolecule.
[0098] A second defined region is the antibody light chain as
targeted by a Protein L affinity matrix. Protein L binds
specifically to Kappa I, II and IV light chains but not Kappa III
nor Gamma light chains. The interaction between Protein L with
antibodies has been mapped and it was noted that hydrogen bonds and
salt bridges are important in binding. A total of 11 hydrophilic
amino acid residues--namely; Ala, Asp, Gin, Glu, Gly, Ile, Leu,
Lys, Phe, Thr, Tyr--of the Protein L domain are important in
forming these bonds. Protein L mimetic affinity supports have been
developed by creating triazine scaffold combinatorial libraries
using structurally similar chemical compounds to the 11 amino acids
disclosed above (WO 2004/035199A). Disclosed within WO2004/035199A
a Protein L mimetic is defined as a ligand having 50% of the
affinity of Protein L for an antibody or fragment and specificity
for the light chain as evidenced by binding of Fab fragments. Any
suitable scaffold disclosed herein or known to those skilled in the
art can be substituted for the triazine scaffold as long as the
characteristics of affinity and specificity for light chain are
retained. Such resins are useful for the immobilization of
antibodies and fragments containing Kappa I, II and IV light
chains. One commercial embodiment of Protein L mimetics is
Fabsorbent.TM. F1P HF (ProMetic Biosciences). This affinity support
meets the criterion for a Protein L mimetic but also binds gamma
light chain containing antibodies and fragments. Therefore, this
affinity support is universally applicable to antibody affinity
binding and conjugation. In an embodiment, the capture resin is
able to bind to an antibody light chain as targeted by a Protein L
affinity matrix.
[0099] A third defined region is the conserved nucleotide domain in
the Fab arm of all antibody isotypes across a wide range of
species. The binding site comprises 4 amino acid residues with the
first being either a Tyr or Phe and the remaining three Tyr, Tyr
and Trp. While the binding pocket location and amino acid
side-chain orientation are conserved in the crystal structure
overlay, there are slight differences in the overall backbone
sequence variation from antibody to antibody and in numbering
schemes. This is demonstrated below by comparing the conserved
nucleotide binding sites for the commercial antibodies Herceptin
and Rituximab. Nucleotide mimetics (non-peptide, peptide,
nucleotide analogue and amino acid) which have been rationally
designed to interact with this domain via one or more of the amino
acids described above are suitable affinity ligands for IgG binding
and conjugation.
TABLE-US-00002 Amino Amino Amino Amino Antibody Acid 1 Acid 2 Acid
3 Acid 4 Herceptin Light Chain Light Chain Heavy Chain Heavy Chain
Tyr 36 Tyr 87 Tyr 95 Trp 110 Rituximab Light Chain Light Chain
Heavy Chain Heavy Chain Phe 35 Tyr 86 Tyr 95 Trp 111
[0100] In an embodiment, the capture resin is able to bind to a
conserved nucleotide domain in the Fab arm of an antibody.
[0101] A fourth defined region is the glycan structures present on
Asn 297 in the CH2 domain of the Fc region of intact antibodies.
m-Aminophenylboronic acid acting as an affinity ligand binds to cis
diol groups on sugar residues such as mannose, galactose or glucose
such that are present with the saccharide moiety of glycoprotein
molecules. A reversible five membered ring complex is furnished
from this interaction. A typical antibody glycan structure is shown
in FIG. 6 to highlight the presence of mannose and galactose in
antibody glycans (Adapted from Arnold et al, Advances in
Experimental Medicine and Biology, 2005, 564, 27-43). In an
embodiment, the capture resin is able to bind to a glycan structure
present on Asn 297 in the CH2 domain of the Fc region of intact
antibodies.
[0102] Ligands can be attached to a range of solid support matrices
well known in the field of affinity chromatography. These include
by example, synthetic polymers such as polyacrylamide,
polyvinylalcohol or polystyrene, especially cross linked synthetic
polymers, inorganic supports such as silica-based supports and in
particular polysaccharide supports such as starch, cellulose and
agarose.
[0103] Specific ligand-supports suitable for antibody binding are
described below:
[0104] `Non Peptide` Protein a, G and L Mimetic Affinity
Supports
[0105] Molecular modelling of the Protein A, G or L interaction
combined with synthetic chemical library screening has enabled
semi-rational design of small molecule mimetics of these proteins
(Li et al, Nature Biotechnology, 1998, 16, 190-195). Examples of
such resins include the commercially available supports mAbsorbent
A1P and FAbsorbent F1P HF (ProMetic Biosciences).
[0106] mAbsorbent A1P and FAbsorbent F1P HF supports are formed on
a triazine scaffold using a multicomponent Ugi reaction
(www.prometicbioscience.com).
[0107] US20010045384 discloses a Protein A mimetic ligand-complex
assembled upon an imino diacetate (IDA) type scaffold. The IDA
scaffold is derivatised with triazyl ligands to afford a
multivalent triazyl ligand-complex.
[0108] WO9808603 describes the isolation of immunoglobulins from
cell culture supernatants, sera, plasma or colostrum using affinity
resins. These affinity resins comprise of synthetic mono or
bicyclic-aromatic or heteroaromatic ligands to facilitate
immunoglobulin purification.
[0109] Another ligand with promise as an antibody affinity resin is
sulfamethazine. Dextran microparticles coupled with sulfamethazine
specifically bind antibodies (Yi et al, Prep. Biochem. Biotechnol.,
2012, 42, 6, 598-610).
[0110] In the selection of the lead candidate ligands described
above many ligands were excluded based on lack of antibody
specificity. It is disclosed herein that specificity is less
important than binding efficiency, capacity and stability for a
solid phase antibody conjugation resin and as such these are not
discounted.
[0111] `Peptide` Protein a, G or L Mimetic Affinity Supports
[0112] A number of Protein A mimetic peptides have been disclosed.
Menegatti identified a hexapeptide with the sequence HWRGWV that
binds to the antibody Fc region (Menegatti et al, Journal of
Separation Science, 2012, 35, 22, 3139-3148. Fassina et al have
identified a Protein A mimetic peptide TG191318 through synthesis
and screening of synthetic multimeric peptide libraries composed of
randomized synthetic molecules with a tetradendate lysine core
(Fassina et al, J. Mol. Recognit., 1996, 9, 564). EP1997826
discloses a peptide comprising X.sub.1-Arg-Thr-Tyr. Lund et al
discloses two peptide ligands suitable for antibody affinity
chromatography (Lund et al, J Chromatogr. A, 2012, 1225, 158-167).
DAAG and D.sub.2AAG contain L-arginine, L-glycine and a synthetic
aromatic acid 2, 6-di-tert-butyl-4-hydroxybenzyl acrylate
(DBHBA)
[0113] Amino Acid Protein A, G or L Mimetic Affinity Supports
[0114] In addition to the complex macromolecular ligands described
above simple amino acids have been proposed as Protein A mimetics
that bind antibodies in the same way (Naik et al, J. Chromatogr. A,
2011, 1218, 1756-1766). An example of this is AbSep a tryptophan
containing polymethacrylate resin with a high affinity for the
Protein A binding site in the Fc region of antibodies. Resins
containing the amino acids Tyrosine, Histidine and Phenylalanine
are also suitable for antibody immobilisation and conjugation
(Bueno et al, J. Chromatogr. B, Biomed. Appl., 1995; 667, 1,
57-67).
[0115] Nucleotide Binding Site Affinity Supports
[0116] Another strategy for developing antibody purification
ligands has exploited the lesser known conserved nucleotide binding
site (NBS) in the Fab variable regions of antibodies (Alves et al,
Anal. Chem., 2012, 84, 7721-7728). The nucleotide analogue
indolebutyric acid has been coupled to a ToyoPearl AF-650-amino M
resin to prepare a support which meets criterion 1-5 above. An
extensive range of other nucleotide analogues useful for antibody
affinity chromatography is described in WO/2012/099949.
[0117] Carbohydrate Binding Resins
[0118] The ligand m-aminophenylboronic acid immobilised on a
variety of supports has been used to purify glycoproteins. The
ligand binds to cis-diol groups on sugar residues such as mannose,
galactose, or glucose that are present within the saccharide moiety
of glycoprotein molecules including antibodies, forming a
reversible five-member ring complex. This complex can be
dissociated by lowering the pH, or by using an elution buffer
containing either Tris or sorbitol.
[0119] A ligand of the capture resin is able to interact with a
biomolecule by specific, reversible and non-covalent bond
interactions between the ligand and the biomolecule, e.g. a
protein, antibody, modified antibody or antibody fragment.
Non-covalent interactions may be classified as ionic, van der
Waals, hydrogen bond or hydrophobic. These interactions work in a
3-dimensional manner to assist in the flexibility and conformation
of the target biomolecule to the ligand of the capture resin. When
in close proximity to the ligand, the biomolecule may infer one,
several or all of these interactions to afford a ligand-biomolecule
complex. The distance between the ligand and the biomolecule and
the polarity and electronegativity of the ligand will determine the
intensity of these interactions. Furthermore, the intensity of
these interactions may be defined as the affinity force. A high
affinity force between a ligand and a biomolecule constitutes a
ligand-biomolecule complex of enhanced stability
(US2009/0240033).
[0120] In an embodiment the capture resin comprises a
non-peptide-based Protein A, Protein G or Protein L mimetic. The
capture resin is able to bind an antibody, modified antibody or
antibody fragment.
[0121] Non-peptide-based Protein A, Protein G or Protein L mimetics
have been used in dye ligand chromatography, which is a mode of
affinity chromatography that utilizes covalently bond textile dyes
immobilised to a solid support such as agarose to purify proteins.
These dyes resemble natural substrates/protein ligands to which
proteins have affinities for. This mode of purification and
separation is often referred to as pseudo-affinity chromatography.
Dye ligand affinity chromatography is non-specific but the
technique is advantageous for a broad binding range for a variety
of proteins. Advances in the purification technique employed
modified dyes to act as competitive inhibitors for a proteins
normal substrate/ligand (P. Dean et al, J. Chromatography, 1979,
165, 3, 301-319). Triazinyl based ligands such as Cibacron Blue
3GA, Procion Red H-3B, Procion Blue MX 3G, Procion Yellow H-A, etc.
are commonly employed and address the concerns of purity, leakage
and toxicity of the original commercial dyes such as Blue Dextran
(Lowe et al, Trends Biotechnology, 1992, 10, 442-448). Triazinyl
ligands have been successfully used for the purification of
albumin, oxidoreductases, decarboxylases, glycolytic enzymes,
nucleases, hydroloases, lyases, synthetases and transferases (N.
Labrou, Methods Mol. Biol. 2002, 147, 129-139). A limitation of
biomimetic dye ligand affinity chromatography is that the affinity
strength from biomolecule to biomolecule is considerably variable
and in many cases a ligand that affords strong affinity strength
for a protein may not be applicable to another protein. Therefore,
it is often a necessity that an extensive and empirical screening
process is undertaken to identify suitable synthetic ligands with
desired affinity for a biomolecule of interest.
[0122] Consequently to assist in the structured elucidation of
suitable ligands that effect affinity binding to a biomolecule a
multivalent scaffold motif has been incorporated into the ligand
structure to provide a construct to which a library of ligands may
be introduced and screened in combination with rigid spatial
separation of the ligand from the support.
[0123] In an embodiment, the ligand of the capture resin has a
structure according to the structures recited in the disclosure of
WO98/08603. The capture resins of WO98/08603 comprise synthetic
mono or bicyclic-aromatic or heteroaromatic ligands to facilitate
immunoglobulin purification. The contents of WO98/08603 relating to
the structure of the capture resin are incorporated herein by
reference. WO98/08603 describes the isolation of immunoglobulins
from cell culture supernatants, sera, plasma or colostrum using
affinity resins.
[0124] In an embodiment, the ligand of the capture resin has a
structure according to the structures recited in the disclosure of
WO2009/141384. The capture resins of WO2009/141384 have the general
formula:
##STR00001##
wherein R.sub.1, R.sub.2 and R.sub.3 represent organic moieties of
a molecular weight of 15-1000 g/mol, the total weight being
200-2000 g/mol, to which the ligand is immobilised to a solid phase
support through an amide bond through one of R.sub.1, R.sub.2 and
R.sub.3. The contents of WO2009/141384 relating to the structure of
the capture resin are incorporated herein by reference.
WO2009/141384 describes that the ligands bind proteinaceous Factor
VII polypeptides.
[0125] In an embodiment, the ligand of the capture resin has a
structure according to the structures recited in the disclosure of
US20010045384. The capture resins of US20010045384 are Protein A
mimetic ligand-complexes assembled upon an imino diacetate (IDA)
type scaffold. The contents of US20010045384 relating to the
structure of the capture resin are incorporated herein by
reference. The IDA scaffold is derivatatised with triazyl ligands
to afford a multivalent triazyl ligand-complex. An illustrative
triazyl ligand complex defined within US20010045384 is shown
below:
##STR00002##
[0126] This Protein A mimetic has been demonstrated for utility as
an affinity purification media for immunoglobulins such as IgG. It
is postulated that the molecular geometry of the adjacent triazine
ligands in the ligand-complex is an advantage using the IDA
scaffold.
[0127] Another illustrative complex defined within US20010045384 is
shown below:
##STR00003##
[0128] This branched multivalent phthalic acid-ligand scaffold
Protein A mimetic ligand-complex was demonstrated to have affinity
for immunoglobulins.
[0129] In an embodiment, the ligand of the capture resin has a
structure according to the structures recited in the disclosure of
WO9710887 and U.S. Pat. No. 6,117,996. The contents of WO9710887
and U.S. Pat. No. 6,117,996 relating to the structure of the
capture resin are incorporated herein by reference. WO9710887 and
U.S. Pat. No. 6,117,996 disclose a triazyl-ligand affinity
construct of the type:
##STR00004##
wherein, (A) represents the covalent attachment point of the
triazine scaffold to a polysaccharide solid support optionally
through a spacer arm interposed between the ligand and the solid
support, and R.sub.1 and Q are optionally substituted ligands with
affinity for proteinaceous materials. The organic moieties are
described as Protein A mimetics and are proposed and exemplified as
alternative purification media to Protein A for the purification of
proteinaceous materials.
[0130] In an embodiment, the ligand of the capture resin has a
structure according to the structures recited in the disclosure of
WO2004/035199. The content of WO2004/035199 relating to the
structure of the capture resin is incorporated herein by reference.
WO2004/035199 discloses the use of a Protein L mimetic comprising
of a branched ligand scaffold of general formula,
##STR00005##
wherein R.sup.1 and R.sup.2 are the same or different and are each
optionally substituted alkyl or aryl ligands, and R.sup.3 is a
solid support optionally attached by a spacer motif. The
triazyl-ligand scaffold has been disclosed as suitable Protein L
mimetic ligands for the affinity binding of immunoglobulin or
fragment antibodies (fAb) thereof. Furthermore, it is disclosed
that these triazyl-ligand scaffolds have preferential binding
affinity for immunoglobulin K and a light chains.
[0131] In an embodiment, the ligand of the capture resin has a
structure according to the structures recited in the disclosure of
US20110046353. The content of US20110046353 relating to the
structure of the capture resin is incorporated herein by reference.
US20110046353 discloses the purification of a fragment antibody
(fAb) from a production medium. Fragment antibodies cannot be
purified on Protein A media. The fAb is characterised as having a
binding domain capable of binding to an antigen and in many
embodiments disclosed within consists of having one heavy chain
(Vh), or a functional fragment thereof, and one light chain (VI),
or a functional fragment thereof, together with at least one other
chain. Defined within are affinity ligands for fAb, consisting of a
branched triazyl scaffold of the formula,
##STR00006##
wherein Q represents the attachment point to a solid support
matrix, optionally with a spacer motif and Groups A and B are
phenyl or naphthyl groups substituted with one or more substituents
capable of hydrogen bonding, preferably one or more of --OH, --SH
or --CO.sub.2H. Excellent results have been reported using
supported affinity ligands commercially available from Prometic
Biosciences under the trade names MAbsorbent A1P and MAbsorbent
A2P.
[0132] In an embodiment, the ligand of the capture resin has a
structure:
##STR00007##
[0133] In an embodiment, the ligand of the capture resin has a
structure:
##STR00008##
[0134] In an embodiment, the ligand of the capture resin has a
structure:
##STR00009##
[0135] In an embodiment, the capture resin is in the form of a
bead. In an embodiment, the size of the bead in terms of the bead
diameter is from about 10 .mu.m to about 2000 .mu.m, preferably
from about 50 .mu.m to about 1000 .mu.m, and most preferably from
about 75 .mu.m to about 500 .mu.m.
[0136] In an embodiment, the capture resin includes a mobile
support made from a material selected from the group consisting of:
Polystyrene, Polystyrene (PS-DVB)--Lightly cross-linked with
divinylbenzene (0.1-5.0% DVB, termed Microporous), Polystyrene
(PS-DVB)--Highly cross-linked with divinylbenzene (5-60% DVB,
termed Macroporous), Polyethylene glycol, Polyethylene glycol
grafted polystyrene (PS-PEG co-polymer), Poly acrylamide,
Controlled Pore Glass (CPG) beads, Silica, Kieselguhr,
Polypropylene, Poly(tetrafluoroethylene), Polyethylene, Cellulose,
Poly methacrylate, Functionalised Monoliths, Functionalised Fibres,
Monolithic columns (such as Nikzad et al, OPRD, 2007, 11, 458-462),
Agarose, Sepharose and Magnetic recoverable polymer beads.
[0137] In a preferred embodiment, the capture resin is a mobile
support made from a material selected from the group consisting of:
Agarose, Sepharose and Cellulose.
[0138] In an embodiment, the capture resin is a commercially
available capture resin such as Fabsorbant.TM. F1P HF resin. In an
embodiment, the capture resin is a commercially available capture
resin such as Mabsorbant.TM. resin.
[0139] Biomolecule:
[0140] In an embodiment, the biomolecule naturally occurs in a
living organism. Alternatively, the biomolecule may be a derivative
of a chemical compound that naturally occurs in a living organism.
For example, the biomolecule may be biomolecule that has been
altered chemically or genetically in a way which does not affects
its biological activity.
[0141] In an embodiment, the biomolecule is an antibody.
[0142] In an embodiment, the biomolecule is a modified antibody,
e.g. an antibody including a non-natural amino acid.
[0143] In an embodiment, the biomolecule is an antibody
fragment.
[0144] In an embodiment, the antibody is a monoclonal antibody.
[0145] In an embodiment, the antibody is trastuzumab.
[0146] In an embodiment, the antibody, modified antibody or
antibody fragment is an immunoglobulin (Ig), e.g. one of the five
human immunoglobulin classes: IgG, IgA, IgM, IgD and IgE. The term
antibody encompasses monoclonal antibodies. The term antibody
encompasses polyclonal antibodies. The term antibody encompasses
antibody fragments so long as they exhibit the desired biological
activity. The antibody can be a human antibody, an animal antibody,
a murine antibody, a humanised antibody or a chimeric antibody that
comprises human and animal sequences.
[0147] The basic unit of the antibody structure is a
heterotetrameric glycoprotein complex of at least 20,000 Daltons,
for example about 150,000 Daltons. An antibody might be at least
900 amino acids in length, for example 1400 amino acids in length.
An antibody may composed of two identical light (L) chains and two
identical heavy (H) chains, linked together by both non-covalent
associations and by di-sulfide bonds. Each heavy and light chain
also has regularly spaced intrachain disulfide bridges. Each heavy
chain is about 50,000 Daltons. Each heavy chain is at least 300
amino acids in length, for example about 450 amino acids in length.
The antibody may be a heavy chain only antibody. Each light chain
is about 20,000 Daltons. Each light chain is at least 100 amino
acids in length, for example about 250 amino acids in length.
[0148] An antibody biomolecule can contain two identical pairs of
polypeptide chains, each pair having one light chain and one heavy
chain. Each light chain and heavy chain in turn consists of two
regions: a variable ("V") region involved in binding the target
antigen, and a constant ("C") region that interacts with other
components of the immune system. The light and heavy chain variable
regions come together in 3-dimensional space to form a variable
region that binds the antigen (for example, a receptor on the
surface of a cell).
[0149] In an embodiment the biomolecule is an antibody fragment.
Antibody fragments comprise a portion of a full length antibody,
generally the antigen binding or variable region thereof.
[0150] Examples of antibody fragments include Fab, pFc', F(ab')2,
and scFv fragments; diabodies; linear antibodies; single-chain
antibody biomolecules; and multispecific antibodies formed from
antibody fragments. An antibody fragment might be at least 10 amino
acids in length, for example an antibody fragment might be at least
20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280 or
300 amino acids in length.
[0151] In an embodiment the biomolecule is a modified antibody or a
modified antibody fragment. By "modified antibody" or "modified
antibody fragment" is meant an antibody that differs from a parent
antibody by virtue of at least one amino acid modification. A
modified antibody or modified antibody fragment refers to an
antibody, which in comparison to the wild-type antibody, is
different with respect to its size, or which is different with
respect to its glycosylation but which has a similar affinity to
its ligand as the wild-type antibody.
[0152] Drug:
[0153] The term "drug" includes any substance that, when
administered into the body of a living organism, alters normal
bodily function. Generally a drug is a substance used in the
treatment, cure, prevention, or diagnosis of disease or used to
otherwise enhance physical or mental well-being. In an embodiment,
the drug is a cytotoxic drug.
[0154] The leading `ultra-potency` (drug) candidates to date are
defined in one of two categories: (i) tubulin inhibitors; and (ii)
DNA interacting agents. Tubulin inhibitors modulate tubulin
polymerization. DNA interacting agents target cellular DNA
[0155] In an embodiment the drug is a tubulin inhibitor.
[0156] In an embodiment, the tubulin inhibitor is selected from the
group consisting of: (a) an auristatin; and (b) a maytansine
derivative.
[0157] In an embodiment, the drug is an auristatin.
[0158] Auristatins include synthetic derivatives of the naturally
occurring compound Dolastatin-10. Auristatins are a family of
antineoplastic/cytostatic pseudopeptides. Dolastatins are
structurally unique due to the incorporation of 4 unusual amino
acids (Dolavaine, Dolaisoleuine, Dolaproine and Dolaphenine)
identified in the natural biosynthetic product. In addition this
class of natural product has numerous asymmetric centres defined by
total synthesis studies by Pettit et al (U.S. Pat. No. 4,978,744).
It would appear from structure activity relationships that the
Dolaisoleuine and Dolaproine residues appear necessary for
antineoplastic activity (U.S. Pat. Nos. 5,635,483 and
5,780,588).
[0159] In an embodiment, the auristatin is selected from the group
consisting of: Auristatin E (AE); Monomethylauristatin E (MMAE);
Auristatin F (MMAF); vcMMAE; and vcMMAF.
[0160] In an embodiment, the drug is a maytansine or a structural
analogue of maytansine.
[0161] In an embodiment, the drug is a maytansine.
[0162] Maytansines include structurally complex antimitotic
polyketides. Maytansines are potent inhibitors of microtubulin
assembly which leads towards apoptosis of tumour cells.
[0163] In an embodiment the maytansine is selected from the group
consisting of: Mertansine (DM1); and a structural analogue of
maytansine such as DM3 or DM4. Preferably, the drug is mertansine
(DM1).
[0164] In an embodiment, the drug is DNA interacting agent. DNA
interacting agents are known as `ultra-potent` (drug)
candidates.
[0165] In an embodiment, the DNA interacting agent is selected from
the group consisting of: (a) calicheamicins, (b) duocarmycins and
(c) pyrrolobenzodiazepines (PBDs).
[0166] In an embodiment, the drug is a calicheamicin.
[0167] Calicheamicin is a potent cytotoxic agent that causes
double-strand DNA breaks, resulting in cell death. Calicheamicin is
a naturally occurring enediyne antibiotic (A. L. Smith et al, J.
Med. Chem., 1996, 39, 11, 2103-2117). Calicheamicin was found in
the soil microorganism Micromonosporaechinospora.
[0168] In an embodiment, the calicheamicin is calicheamicin gamma
1.
[0169] In an embodiment, the drug is a duocarmycin.
[0170] Duocarmycins are potent anti-tumour antibiotics that exert
their biological effects through binding sequence-selectively in
the minor groove of DNA duplex and alkylating the N3 of adenine (D.
Boger, Pure & Appl. Chem., 1994, 66, 4, 837-844).
[0171] In an embodiment, the duocarmycin is selected from the group
consisting of: Duocarmycin A; Duocarmycin B1; Duocarmycin B2;
Duocarmycin C1; Duocarmycin C2; Duocarmycin D; Duocarmycin SA;
Cyclopropylbenzoindole (CBI) duocarmycin; Centanamycin; Rachelmycin
(CC-1065); Adozelesin; Bizelesin; and Carzelesin.
[0172] In an embodiment, the drug is a pyrrolobenzodiazepine.
[0173] Pyrrolobenzodiazepines (PBDs) are a class of naturally
occurring anti-tumour antibiotics. Pyrrolobenzodiazepines are
foundin Streptomyces. PBDs exert their anti-tumour activity by
covalently binding to the DNA in the minor groove specifically at
purine-guanine-purine units. They insert on to the N2 of guamine
via an aminal linkage and, due to their shape, they cause minimal
disruption to the DNA helix. It is believed that the formation of
the DNA-PBD adduct inhibits nucleic acid synthesis and causes
excision-dependent single and double stranded breaks in the DNA
helix. As synthetic derivatives the joining of two PBD units
together via a flexible polymethylene tether allows the PBD dimers
to cross-link opposing DNA strands producing highly lethal
lesions.
[0174] In an embodiment, the drug is a synthetic derivative of two
pyrrolobenzodiazepines units joined together via a flexible
polymethylene tether.
[0175] In an embodiment, the pyrrolobenzodiazepine is selected from
the group consisting of: Anthramycin (and dimers thereof);
Mazethramycin (and dimers thereof); Tomaymycin (and dimers
thereof); Prothracarcin (and dimers thereof); Chicamycin (and
dimers thereof); Neothramycin A (and dimers thereof); Neothramycin
B (and dimers thereof); DC-81 (and dimers thereof); Sibiromycin
(and dimers thereof); Porothramycin A (and dimers thereof);
Porothramycin B (and dimers thereof); Sibanomycin (and dimers
thereof); Abbeymycin (and dimers thereof); SG2000; and SG2285.
[0176] In an embodiment, the drug is a drug that targets DNA
interstrand crosslinks through alkylation. A drug that targets DNA
interstrand crosslinks through alkylation is selected from: a DNA
targeted mustard; a guanine-specific alkylating agent; and a
adenine-specific alkylating agent.
[0177] In an embodiment, the drug is a DNA targeted mustard. For
example, the DNA targeted mustard may be selected from the group
consisting of: an oligopyrrole; an oligoimidazole; a
Bis-(benzimidazole) carrier; a Polybenzamide Carrier; and a
9-Anilinoacridine-4-carboxamide carrier.
[0178] In an embodiment, the drug is selected from the group
consisting of: Netropsin; Distamycin; Lexitropsin; Tallimustine;
Dibromotallimustine; PNU 157977; and MEN 10710.
[0179] In an embodiment, the drug is a Bis-(benzimidazole) carrier.
Preferably, the drug is Hoechst 33258.
[0180] A guanine-specific alkylating agent is a highly
regiospecific alkylating agents that reacts at specific nucleoside
positions.
[0181] In an embodiment, the drug is a guanine-specific alkylating
agent selected from the group consisting of: a G-N2 alkylators; a
A-N3 alkylator; a mitomycin; a carmethizole analogue; a
ecteinascidin analogue.
[0182] In an embodiment, the mitomycin is selected from: Mitomycin
A; Mitomycin C; Porfiromycin; and KW-2149.
[0183] In an embodiment, the a carmethizole analogue is selected
from: Bis-(Hydroxymethyl)pyrrolizidine; and NSC 602668.
[0184] In an embodiment, the ecteinascidin analogue is
Ecteinascidin 743.
[0185] Adenine-specific alkylating agents are regiospecific and
sequence-specific minor groove alkylators reacting at the N3 of
adenines in polypyrimidines sequences. Cyclopropaindolones and
duocamycins may be defined as adenine-specific alkylators.
[0186] In an embodiment, the drug is a cyclopropaindolone analogue.
Preferably, the drug is selected from: adozelesin; and
carzelesin.
[0187] In an embodiment, the drug is a benz[e]indolone. Preferably,
the drug is selected from: CBI-TMI; and iso-CBI.
[0188] In an embodiment, the drug is bizelesin.
[0189] In an embodiment, the drug is a Marine Antitumor Drug.
Marine Antitumor Drugs has been a developing field in the antitumor
drug development arena (I. Bhatnagar et al, Mar. Drugs 2010, 8,
P2702-2720 and T. L. Simmons et al, Mol. Cancer Ther. 2005, 4(2),
P333-342). Marine organisms including sponges, sponge-microbe
symbiotic association, gorgonian, actinomycetes, and soft coral
have been widely explored for potential anticancer agents.
[0190] In an embodiment, the drug is selected from: Cytarabine,
Ara-C; Trabectedin (ET-743); and EribulinMesylate.
[0191] In an embodiment, the EribulinMesylate is selected from:
(E7389); Soblidotin (TZT 1027); Squalamine lactate;
CemadotinPlinabulin (NPI-2358); Plitidepsin; Elisidepsin; Zalypsis;
Tasidotin, Synthadotin; (ILX-651); Discodermolide; HT1286; LAF389;
Kahalalide F; KRN7000; Bryostatin 1; Hemiasterlin (E7974);
Marizomib; Salinosporamide A; NPI-0052); LY355703; CRYPTO 52;
Depsipeptide (NSC630176); Ecteinascidin 743; Synthadotin;
Kahalalide F; Squalamine; Dehydrodidemnin B; Didemnin B; Cemadotin;
Soblidotin; E7389; NVP-LAQ824; Discodermolide; HTI-286; LAF-389;
KRN-7000 (Agelasphin derivative); Curacin A; DMMC; Salinosporamide
A; Laulimalide; Vitilevuamide; Diazonamide; Eleutherobin;
Sarcodictyin; Peloruside A; Salicylihalimides A and B;
Thiocoraline; Ascididemin; Variolins; Lamellarin D; Dictyodendrins;
ES-285 (Spisulosine); and Halichondrin B.
[0192] The following drugs are also encompassed by the present
invention: Amatoxins (.alpha.-amanitin)-bicyclic octapeptides
produced by basidiomycetes of the genus Amanita, e.g. the Green
Deathcap mushroom; Tubulysins; Cytolysins; dolabellanins;
Epothilone A, B, C, D, E, F.
[0193] Epothilones--constitute a class of non-taxane tubulin
polymerisation agents and are obtained by natural fermentation of
the myxobacterium Sorangiumcellulosum. These moieties possess
potent cytotoxic activity which is linked to the stabilisation of
microtubules and results in mitotic arrest at the G2/M transition.
Epothilones have demonstrated potent cytotoxicity across a panel of
cancer cell lines and has often exhibited greater potency than
paclitaxel (X.: Pivot et al, European Oncology, 2008; 4(2),
P42-45).
[0194] In an embodiment, the drug is amatoxin.
[0195] In an embodiment, the drug is tubulysin.
[0196] In an embodiment, the drug is cytolysin.
[0197] In an embodiment, the drug is dolabellanin.
[0198] In an embodiment, the drug is epothilone.
[0199] The following drugs are also encompassed by the present
invention. In an embodiment, the drug is selected from:
Doxorubicin; Epirubicin; Esorubicin; Detorubicin;
Morpholino-doxorubicin; Methotrexate; Methopterin; Bleomycin;
Dichloromethotrexate; 5-Fluorouracil;
Cytosine-.beta.-D-arabinofuranoside; Taxol; Anguidine; Melphalan;
Vinblastine; Phomopsin A; Ribosome-inactivating proteins (RIPs);
Daunorubicin; Vinca alkaloids; Idarubicin; Melphalan; Cis-platin;
Ricin; Saporin; Anthracyclines; Indolino-benzodiazepines;
6-Mercaptopurine; Actinomycin; Leurosine; Leurosideine;
Carminomycin; Aminopterin; Tallysomycin; Podophyllotoxin;
Etoposide; Hairpin polyamides; Etoposide phosphate; Vinblastine;
Vincristine; Vindesine; Taxotere retinoic acid; N8-acetyl
spermidine; Camptothecin; Esperamicin; and Ene-diynes.
[0200] In an embodiment, the drug is Doxorubicin.
[0201] In an embodiment, the drug is Epirubicin.
[0202] In an embodiment, the drug is Esorubicin.
[0203] In an embodiment, the drug is Detorubicin.
[0204] In an embodiment, the drug is Morpholino-doxorubicin.
[0205] In an embodiment, the drug is Methotrexate.
[0206] In an embodiment, the drug is Methopterin.
[0207] In an embodiment, the drug is Bleomycin.
[0208] In an embodiment, the drug is Dichloromethotrexate.
[0209] In an embodiment, the drug is 5-Fluorouracil.
[0210] In an embodiment, the drug is
Cytosine-1-D-arabinofuranoside.
[0211] In an embodiment, the drug is Taxol.
[0212] In an embodiment, the drug is Anguidine.
[0213] In an embodiment, the drug is Melphalan.
[0214] In an embodiment, the drug is Vinblastine.
[0215] In an embodiment, the drug is Phomopsin A.
[0216] In an embodiment, the drug is Ribosome-inactivating proteins
(RIPs).
[0217] In an embodiment, the drug is Daunorubicin.
[0218] In an embodiment, the drug is Vinca alkaloids.
[0219] In an embodiment, the drug is Idarubicin.
[0220] In an embodiment, the drug is Melphalan.
[0221] In an embodiment, the drug is Cis-platin.
[0222] In an embodiment, the drug is Ricin.
[0223] In an embodiment, the drug is Saporin.
[0224] In an embodiment, the drug is Anthracyclines.
[0225] In an embodiment, the drug is Indolino-benzodiazepines.
[0226] In an embodiment, the drug is 6-Mercaptopurine.
[0227] In an embodiment, the drug is Actinomycin.
[0228] In an embodiment, the drug is Leurosine.
[0229] In an embodiment, the drug is Leurosideine.
[0230] In an embodiment, the drug is Carminomycin.
[0231] In an embodiment, the drug is Aminopterin.
[0232] In an embodiment, the drug is Tallysomycin.
[0233] In an embodiment, the drug is Podophyllotoxin.
[0234] In an embodiment, the drug is Etoposide.
[0235] In an embodiment, the drug is Hairpin polyamide.
[0236] In an embodiment, the drug is Etoposide phosphate.
[0237] In an embodiment, the drug is Vinblastine.
[0238] In an embodiment, the drug is Vincristine.
[0239] In an embodiment, the drug is Vindesine.
[0240] In an embodiment, the drug is Taxotere retinoic acid.
[0241] In an embodiment, the drug is N8-acetyl spermidine.
[0242] In an embodiment, the drug is Camptothecin.
[0243] In an embodiment, the drug is Esperamicin.
[0244] In an embodiment, the drug is Ene-diyne.
[0245] Biomolecule-Drug-Conjugates:
[0246] In accordance with the present invention there is provided a
biomolecule-drug-conjugate obtainable by a process of the present
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0247] Embodiments of the invention are further described
hereinafter with reference to the accompanying drawings, in
which:
[0248] FIG. 1--HIC Analysis of Solid Phase Herceptin vcMMAE
Conjugates produced by Example 2. Traces from bottom to top
Herceptin-vcE.sub.1.3, Herceptin-vcE.sub.2.4,
Herceptin-vcE.sub.3.4, Herceptin-vcE.sub.4.4. RT 4.3
min--Unconjugated Herceptin, RT 5.9 min--Drug antibody ratio of 2,
RT 7.5 min--Drug antibody ratio of 4, RT 8.9 min--Drug antibody
ratio of 6 and RT 9.8 min--Drug antibody ratio of 8.
[0249] FIG. 2--SEC Analysis of Solid Phase Herceptin vcMMAE
Conjugates produced by Example 2. Traces from bottom to top
Herceptin, Herceptin-vcE.sub.1.3, Herceptin-vcE.sub.2.4,
Herceptin-vcE.sub.3.4, Herceptin-vcE.sub.4.4.
[0250] FIG. 3--HIC Analysis of Chromatographic Flow Solid Phase
Herceptin vcMMAE Conjugates. HIC analysis of solution phase
Herceptin vcMMAE conjugate (upper panel), Column A manufactured
Herceptin vcMMAE (middle panel), Column B manufactured vcMMAE
(lower panel).
[0251] FIG. 4--SEC Analysis of Solid Phase Herceptin vcMMAE
Conjugates. SEC analysis of solution phase Herceptin vcMMAE
conjugate (upper panel), Column A manufactured Herceptin vcMMAE
(middle panel), Column B manufactured vcMMAE (lower panel).
[0252] FIG. 5--Illustration of possible combination of orthogonal
amino acid side chains and reactive chemistry (adapted from Ambryx
presentation at Hanson Wade ADC summit meeting in February
2012).
[0253] FIG. 6--Depiction of a typical antibody glycan structure to
highlight the presence of mannose and galactose in antibody glycans
(Adapted from Arnold et al, Advances in Experimental Medicine and
Biology, 2005, 564, 27-43). Glycan structure and isoforms. A:
General nomenclature for glycans; B: Predominant glycan structures
of IgGs; G: Galactose units; and F: Fucose units.
DETAILED DESCRIPTION
[0254] Throughout the description and claims of this specification,
the words "comprise" and "contain" and variations of them mean
"including but not limited to", and they are not intended to (and
do not) exclude other moieties, additives, components, integers or
steps. Throughout the description and claims of this specification,
the singular encompasses the plural unless the context otherwise
requires. In particular, where the indefinite article is used, the
specification is to be understood as contemplating plurality as
well as singularity, unless the context requires otherwise.
[0255] Features, integers, characteristics, compounds, chemical
moieties or groups described in conjunction with a particular
aspect, embodiment or example of the invention are to be understood
to be applicable to any other aspect, embodiment or example
described herein unless incompatible therewith. All of the features
disclosed in this specification (including any accompanying claims,
abstract and drawings), and/or all of the steps of any method or
process so disclosed, may be combined in any combination, except
combinations where at least some of such features and/or steps are
mutually exclusive. The invention is not restricted to the details
of any foregoing embodiments. The invention extends to any novel
one, or any novel combination, of the features disclosed in this
specification (including any accompanying claims, abstract and
drawings), or to any novel one, or any novel combination, of the
steps of any method or process so disclosed.
[0256] The reader's attention is directed to all papers and
documents which are filed concurrently with or previous to this
specification in connection with this application and which are
open to public inspection with this specification, and the contents
of all such papers and documents are incorporated herein by
reference.
EXAMPLES
[0257] The following techniques are used in the examples.
[0258] Size Exclusion Chromatography (SEC)
[0259] Size exclusion chromatography was performed using a TOSOH
Bioscience TSK-Gel.RTM. GW3000SWxI column in 0.2M potassium
phosphate pH 6.95 with 0.25 mM potassium chloride and 10% IPA at a
flow rate of 0.5 ml/min. Aggregation state of the conjugate was
determined by integration of eluted peak area absorbance at 280
nm.
[0260] Hydrophobic Interaction Chromatography (HIC)
[0261] Hydrophobic interaction chromatography was performed using a
TOSOH TSK-Gel.RTM. butyl NPR column with a linear gradient of
0-100% buffer A to B over 12 minutes at a flow rate of 0.8 ml/min.
Where buffer A is 1.5 M ammonium acetate pH 6.95 with 25 mM sodium
phosphate and buffer B is 25 mM sodium phosphate pH 6.95 with 25%
IPA. Antibody drug ratio of the conjugate was determined by
integration of eluted peak area absorbance at 280 nm.
[0262] Reverse Phase Chromatography (RP-PLRP)
[0263] Reverse phase (polymer labs PLRP) chromatography was
performed using an Agilent PLRP-S PL1912-1502 column with a
gradient of 25-95% buffer A to B over 31 minutes at a flow rate of
0.25 ml/min. Where buffer A is Water with 0.05% TFA and buffer B is
ACN with 0.04% TFA. Samples were reduced pre injection with 20 mM
sodium borate pH 8.4 pcontaining 50 mM DTT at 37.degree. C. for 15
minutes. Antibody drug ratio of the conjugate was determined by
integration of eluted peak area absorbance at 280 nm.
[0264] Drug to Antibody Ratio by UV Analysis
[0265] For UV analysis the sample was added to a 400 ul quartz
cuvette with a path length of 1 cm and the absorbance at 252 nm and
280 nm measured on a Thermo scientific multiskan GO
spectrophotometer. The 252 nm and 280 nm data was used to calculate
Drug antibody ratio based on published molar extinction
coefficients for Herceptin and DM1 at these wavelengths.
Example 1--Solid Phase Antibody Drug Conjugate Screening
[0266] This example demonstrates that immobilized antibodies can be
conjugated to a defined drug loading with a generic process that
negates the need for process development. This approach is suitable
for adapting to 96 well plate high throughput screening.
[0267] Herceptin (0.5 of 1 mg/ml in PBS, pH 7.4) was bound to 100l
(settled resin volume) of Fabsorbant.TM. F1P HF resin equilibrated
in PBS by mixing the resin slurry and antibody solution gently for
60 minutes. Unbound Herceptin was removed by washing the resin with
PBS, 2 mM EDTA and the resin finally re-suspended in 0.5 ml
PBS/EDTA.
[0268] The bound Herceptin (Her) was reduced by adding
tris-(2-carboxyethyl)phosphine hydrochloride to a final
concentration of 2 mM and then incubating the suspension at ambient
temperature for 18 hours. The resin was washed with PBS/EDTA to
remove unreacted TCEP and then re-suspended in 4751l PBS/EDTA.
[0269] vcMMAE (vcE), N-ethyl maleimide (NEM) and dimethylacetamide
(DMA) were added to achieve final concentrations of 1 mM maleimide
(total vcE and NEM) and 5% v/v DMA. The ratio of vcE to NEM was
varied 100:0, 75:25, 50:50, 25:75 and 0:100. The reduced antibody
was conjugated by incubating the resin suspension at ambient for 60
minutes. The resin was washed sequentially with PBS/EDTA/5% v/v DMA
and 0.1M Glycine pH 5.0.
[0270] The conjugates were eluted with 0.1M glycine pH3.0. The
eluted conjugates were collected into 2% v/v of 1M
tris(hydroxymethyl)aminoethane (TRIS) to neutralise them.
[0271] The neutralised conjugates were then analysed by Size
Exclusion Chromatography and Reverse Phase Chromatography (Polymer
Labs, PLRP) Chromatography to determine the percentage aggregate
and average drug loading.
[0272] The results are summarized in Table 1 below:
TABLE-US-00003 Mass of Her Bound Ratio of Drug to Antibody (mg/ml
resin) vcE:NEM % Aggregate ratio (DAR) 10 100:0 9.72 7.9 10 75:25
4.69 5.7 10 50:50 3.08 4.4 10 25:75 0.80 2.8 10 0:100 0.42 0.0
[0273] The aggregate content of even the highest drug loaded
conjugates is acceptable for further evaluation in antigen binding
and cell based assays. The sequential washes with PBS/ETDA/5% v/v
DMA and then 0.1M glycine pH5.0 ensure the final conjugates are
free from unreacted drug linker, NEM and solvent and do not
compromise interpretation of bioassay data. With Fabsorbant.TM. F1P
HF resin this approach is useful for screening panels of murine
monoclonals as part of clone selection for subsequent antibody drug
conjugation development, for producing ADCs direct from tissue
culture supernatants containing both intact and Fab fragment
antibodies.
Example 2--Solid Phase Partial TCEP Reduction in Batch Mode
[0274] This example shows that immobilized antibodies can be
conjugated to a defined drug loading by partial reduction of the
interchain disulphide bonds followed by conjugation with vcMMAE and
that product quality is enhanced relative to the same conjugates
made in solution.
[0275] Herceptin (0.5 ml of 2 mg/ml PBS, pH 7.4) was bound to 100l
(settled resin volume) of Fabsorbant.TM. F1P HF resin equilibrated
in PBS by mixing the resin slurry and antibody solution gently for
30 minutes. Unbound Herceptin was removed by washing the resin with
PBS, 2 mM EDTA and the resin finally re-suspended in 0.5 ml
PBS/EDTA.
[0276] The bound Herceptin was reduced by adding
tris-(2-carboxyethyl)phosphine hydrochloride to a ratio of 1 to 4
moles of TCEP per mole of Herceptin and then incubating the
suspension at ambient temperature for 2 hours.
[0277] vcMMAE and Dimethylacetamide (DMA) were added to achieve 2.5
to 10 moles of vcMMAE per mole of Herceptin and 5% v/v DMA and the
conjugation allowed to proceed for 30 minutes at ambient. N-Acetyl
cysteine (NAC) was added to quench unreacted vcMMAE and allowed to
react for 20 minutes before the resin was washed sequentially with
PBS/EDTA/5% v/v DMA and 0.1M glycine pH5.0.
[0278] The conjugates eluted with 0.1M glycine pH3.0. The eluted
conjugates were collected into 2% v/v of 1M
tris(hydroxymethyl)aminoethane (TRIS) to neutralise them.
[0279] An equivalent series of solution phase conjugates of
Herceptin with vcMMAE with matched DAR were produced and analysed
to provide a comparison of solid phase and solution phase conjugate
quality.
[0280] The eluted conjugates were then analysed by Hydrophobic
Interaction Chromatography (FIG. 1) and Size Exclusion
Chromatography (FIG. 2) to determine the percentage aggregate and
average drug loading.
[0281] The results are summarized in Table 2 below:
TABLE-US-00004 Solution Solid DAR % Aggregate % Aggregate 0
(Herceptin) 0.2 1.3 0.4 0.3 2.4 0.7 0.3 3.4 1.1 0.3 4.4 1.5 0.3
[0282] The data show that on solid supports the relationship
between TCEP to antibody ratio and final drug loading is linear. In
addition when compared with an equivalent conjugate made in
solution the solid phase conjugates show a lower percentage
aggregation.
Example 3--Solid Phase Partial TCEP Reduction on Column
[0283] This example shows that immobilized antibody conjugation can
be adapted to a chromatographic flow process with excellent
reproducibility.
[0284] Herceptin (5 ml of 2 mg/ml PBS, pH 7.4) was bound to a 1 ml
column of Fabsorbant.TM. F1P HF resin (previously equilibrated in
PBS) by loading at 120 cm/hr. The bound Herceptin was prepared for
reduction by equilibrating the resin with PBS, 2 mM EDTA.
[0285] A micro peristaltic pump was used to create a small volume
PBS/EDTA recirculation loop through the column (approximately 200
.mu.L external to the column) to which TCEP was added to give a
molar ratio of 2 TCEP per mole of Herceptin. This was allowed to
recirculate for 120 minutes at ambient to reduce the Herceptin.
[0286] The contents of the reservoir and column were flushed to
waste and replaced with PBS/EDTA/5% v/v DMA to which vcMMAE was
added to give a molar ratio of 5 vcMMAE per mole of reduced
Herceptin. This was allowed to recirculate for 60 minutes at
ambient to conjugate the reduced Herceptin.
[0287] N-Acetyl cysteine (NAC) was added to quench unreacted vcMMAE
and allowed to react for 20 minutes before the resin was washed
sequentially with PBS/EDTA/5% v/v DMA and 0.1M glycine pH5.0.
[0288] The conjugates were eluted with 0.1M glycine pH 3.0. The
eluted conjugates were collected into 2% v/v of 1M
tris(hydroxymethyl)aminoethane (TRIS) to neutralise them.
[0289] The process was repeated in an independent second experiment
using a second column/operator.
[0290] The eluted conjugates were then analysed by Hydrophobic
Interaction Chromatography (FIG. 3) and Size Exclusion
Chromatography (FIG. 4) to determine the percentage aggregate and
average drug loading.
[0291] The results are summarized in Table 3 below:
TABLE-US-00005 Preparation Method DAR % Aggregate Herceptin 0 0.2
Solution Phase 2.4 0.6 Column A 2.4 0.3 Column B 2.4 0.3
[0292] The data shows that when adapted to a chromatographic flow
mode the conjugation of vcMMAE to Herceptin is consistent with
respect to average drug loading and aggregate generation. The DAR
achieved in batch mode and chromatographic mode is the same when
TCEP to antibody ratio is matched.
Example 4--Solid Phase Herceptin Conjugation with DM1 in Batch Mode
Via SMCC Activation of Lysine Side Chains
[0293] This example shows that immobilized antibodies can be
conjugated on the side chain of lysine by modification with SMCC
followed conjugation with DM1 and that product quality is enhanced
relative to the same conjugates made in solution.
[0294] Herceptin (0.5 ml of 4 mg/ml PBS, pH7.4) was bound to 100
.mu.l (settled resin volume) of Fabsorbant.TM. F1P HF resin
equilibrated in PBS by mixing the resin slurry and antibody
solution gently for 30 minutes. Unbound Herceptin was removed by
washing the resin with PBS followed by `Modification Buffer` (50 mM
NaPi, 150 mM NaCl, 2 mM EDTA pH6.7) and the resin finally
re-suspended in modification buffer containing 5% v/v DMA.
[0295] The bound Herceptin was modified by adding
succinimidyl-4-(N-maleimidomethyl)cyclohexyl-1-carboxylate (SMCC)
to a ratio of 5 to 20 moles of SMCC per mole of Herceptin and then
incubating the suspension at ambient temperature for 4 hours.
Unreacted SMCC was removed by washing the resin with PBS/5% v/v DMA
followed by `Conjugation Buffer` (35 mM sodium citrate, 150 mM
NaCl, 2 mM EDTA pH5.0) and the resin finally re-suspended in
conjugation buffer containing 3% v/v DMA.
[0296] DM1 was added to achieve 15 moles of DM1 per mole of
Herceptin and the conjugation allowed to proceed for 18 hours at
ambient. The resin was then washed sequentially with PBS/EDTA/5%
v/v DMA and 0.1M glycine pH5.0.
[0297] The conjugates were eluted with 0.1M glycine pH3.0. The
eluted conjugates was collected into 2% v/v of 1M
tris(hydroxymethyl)aminoethane (TRIS) to neutralise them.
[0298] An equivalent solution phase conjugate of Herceptin with DM1
with matched DAR was produced by reacting Herceptin with 7.6 moles
of SMCC followed by 5 moles of DM1 per mole of Herceptin and
analysed to provide a comparison of solid phase and solution phase
conjugate quality. The concentration of Herceptin during the
modification and conjugation reactions was 10 and 5 mg/ml
respectively.
[0299] The eluted conjugates were then analysed by Size Exclusion
Chromatography and UV to determine the percentage aggregate and
average drug loading.
[0300] The results are summarized in Table 4 below:
TABLE-US-00006 [Herceptin] during Production Method conjugation
mg/ml DAR % Aggregate Solution 5 3.6 3.2 Solid Phase 20 1.7 1.8 2.6
2.8 3.5 3.0 4.8 3.5
[0301] The data shows that on solid supports lysine side-chain
conjugation is possible and that the relationship between SMCC to
antibody ratio and final drug loading is linear.
[0302] In addition when compared with an equivalent conjugate made
in solution the solid phase conjugates show an equivalent
percentage aggregation despite a four-fold increase in protein
concentration during the conjugation reaction.
* * * * *